Typewriter Therapeutics, Inc., a biotech company developing safe, durable and re-dosable genetic medicines with curative impact for patients with cancer, autoimmune diseases, and severe genetic diseases, today emerged from stealth with $56 million in Series A financing led by AN Venture Partners and RA Capital Management with participation from ANRI, Gemseki, and SBI US Gateway Fund. In addition, Typewriter announced the appointments of Matthew Stanton, PhD, as Chief Executive Officer, Leanne Peiser, DPhil, as Chief Scientific Officer, and Mikael Dolsten, MD, PhD, as a member of the company’s board of directors. Ken Horne, Managing Partner at ANV, continues in his role as Chair of the Board at Typewriter.
Typewriter’s Target-Primed Reverse Transcription (TPRT) technology platform is built on the R2 retrotransposon, a natural gene-insertion system discovered by the company's scientific co-founders, including Haruhiko Fujiwara, PhD, professor emeritus of The University of Tokyo. Typewriter’s two-part, all-RNA therapy comprises a payload mRNA to make the R2 protein and a second RNA containing the therapeutic gene flanked by sequences to recruit the R2 protein. Inside the cell, the two assemble into an active complex that inserts the gene into the specific target site by TPRT. The R2 machinery then degrades along with the mRNA, leaving only the inserted gene at its intended location.
Typewriter’s initial focus will be on two high-value indications with life-changing potential to patients: in vivo CAR T and genetic liver diseases. The company’s first NHP studies are planned for late 2026.For the full announcement, please see Typewriter Therapeutics’ press release here.
About Typewriter Therapeutics
Typewriter Therapeutics is a start-up company that focuses on developing and commercializing RNA-based gene therapies for patients suffering from cancer, autoimmune, and severe genetic disorders. Typewriter’s cutting-edge platform technology enables the targeted insertion of whole therapeutic genes to create safer, durable, and re-dosable medicines. Founded in February 2022, the company builds on the research of Professor Emeritus Haruhiko Fujiwara of the University of Tokyo on transposons. With research facilities in Tokyo and Cambridge, USA, Typewriter is committed to bringing Japan-originated technology to the global stage. For more information, visit www.typewritertx.com.
Media Contacts
Email: info@an.vc
